NEC
Corporation (NEC; TSE: 6701) and BostonGene Corporation
(BostonGene), a Boston, Mass-based biomedical software company, today
announced a US$50M series A strategic investment in BostonGene by NEC.
This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20190425005239/en/
BostonGene, a pioneer in the use of biomedical software for advanced
patient analysis, has discovered, developed, and patented a holistic
approach to cancer treatment by defining the optimal therapy combination
for individual patients, with a particular focus on immuno- and targeted
therapies. BostonGene’s solution includes:
-
Genome and transcriptome sequencing methods to create a patient’s
molecular profile. -
Algorithms that estimate the immune fitness and cancer characteristics
of a patient. -
A continuously updated expert-curated and Artificial Intelligence
(AI)-driven database of cancer research and clinical information. -
Cloud-native software that delivers a patient-prioritized list of best
treatment options based on comprehensive data analysis of the tumor
and its microenvironment.
Founded in 2015, BostonGene has evaluated its solution utilizing
extensive data in close collaboration with many leading cancer centers
across the U.S., and has a robust intellectual property portfolio.
The funding will allow BostonGene to accelerate its long-term strategy,
enable the expansion of the company’s development efforts, advance its
collaboration programs, and support the growth of its talented and
diverse team.
“As demonstrated by its remarkable growth and early widespread adoption,
BostonGene is leading the precision medicine market in the innovation
and development of a mission-critical computing platform,” said Osamu
Fujikawa, Senior Vice President and Head of the Business Innovation Unit
at NEC Corporation. “NEC and BostonGene share a common vision of the
immense potential of an AI-driven approach to cancer immunotherapy.
Leveraging the strengths of both companies we will be able to improve
the survival rate and quality of life for cancer patients.”
“Transforming and personalizing medicine, from treating a diagnosis to
treating the person, is becoming a reality with BostonGene’s unique
breakthrough platform. Our early successes validate the market need and
the potential of our solution to truly transform cancer treatment and
dramatically improve patients’ chances for survival and quality of life.
An investment of this magnitude will support our vision, mission and
strategy, as well as the formation of synergies with the NEC Health Tech
business to create meaningful new opportunities,” said Andrew Feinberg,
President and CEO of BostonGene.
About NEC Corporation
NEC Corporation is a leader in the
integration of IT and network technologies that benefit businesses and
people around the world. The NEC Group globally provides “Solutions for
Society” that promote the safety, security, efficiency and equality of
society. Under the company’s corporate message of “Orchestrating a
brighter world,” NEC aims to help solve a wide range of challenging
issues and to create new social value for the changing world of
tomorrow. For more information, visit NEC at http://www.nec.com.
About BostonGene Corporation
BostonGene Corporation is
pioneering the use of biomedical software for advanced patient analysis
and personalized therapy decision making in the fight against cancer.
BostonGene’s unique solution performs sophisticated analytics to aid
clinicians in their evaluation of viable treatment options for each
patient’s individual genetics, tumor and tumor microenvironment,
clinical characteristics and disease profile. BostonGene’s mission is to
enable physicians to provide every patient with the highest probability
of survival through optimal cancer treatments using advanced,
personalized therapies. For more information, visit BostonGene at http://www.BostonGene.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190425005239/en/